Theranexus SA - Asset Resilience Ratio

Latest as of June 2025: 66.62%

Theranexus SA (ALTHX) has an Asset Resilience Ratio of 66.62% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Theranexus SA for a breakdown of total debt and financial obligations.

Liquid Assets

€3.02 Million

≈ $3.53 Million USD Cash + Short-term Investments

Total Assets

€4.53 Million

≈ $5.30 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Theranexus SA's Asset Resilience Ratio has changed over time. See Theranexus SA (ALTHX) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Theranexus SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ALTHX stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€1.51 Million	33.31%
Short-term Investments	€1.51 Million	33.31%
Total Liquid Assets	€3.02 Million	66.62%

Asset Resilience Insights

Very High Liquidity: Theranexus SA maintains exceptional liquid asset reserves at 66.62% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Theranexus SA Industry Peers by Asset Resilience Ratio

Compare Theranexus SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Aktis Oncology, Inc. Common stock NASDAQ:AKTS	Biotechnology	23.64%
Janux Therapeutics Inc NASDAQ:JANX	Biotechnology	91.79%
Neurotech International Ltd AU:NTI	Biotechnology	0.22%
SynCore Biotechnology Co Ltd TWO:4192	Biotechnology	2.58%
Uniqure NV NASDAQ:QURE	Biotechnology	10.94%
Jazz Pharmaceuticals plc F:J7Z	Biotechnology	6.34%
Brainstorm Cell Therapeutics Inc NASDAQ:BCLI	Biotechnology	0.00%
Altimmune Inc NASDAQ:ALT	Biotechnology	82.06%

Annual Asset Resilience Ratio for Theranexus SA (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Theranexus SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	13.49%	€504.56K ≈ $589.88K	€3.74 Million ≈ $4.37 Million	-69.47pp
2021-12-31	82.97%	€14.01 Million ≈ $16.38 Million	€16.89 Million ≈ $19.75 Million	+54.34pp
2020-12-31	28.63%	€5.00 Million ≈ $5.85 Million	€17.47 Million ≈ $20.42 Million	-49.79pp
2019-12-31	78.42%	€12.05 Million ≈ $14.09 Million	€15.37 Million ≈ $17.97 Million	-6.65pp
2018-12-31	85.07%	€16.03 Million ≈ $18.75 Million	€18.85 Million ≈ $22.04 Million	+72.96pp
2016-12-31	12.11%	€348.87K ≈ $407.86K	€2.88 Million ≈ $3.37 Million	-39.08pp
2015-12-31	51.19%	€1.40 Million ≈ $1.63 Million	€2.73 Million ≈ $3.19 Million	--

pp = percentage points

About Theranexus SA

PA:ALTHX France Biotechnology

Market Cap

$54.40 Million

€46.53 Million EUR

Market Cap Rank

#22431 Global

#355 in France

Share Price

€3.38

Change (1 day)

-1.74%

52-Week Range

€0.45 - €4.37

All Time High

€22.70